Keywords: Roche, Zelboraf, UK, NICE, Metastatic melanoma

UK's NICE denies NHS access to Roche melanoma drug Zelboraf

Article | 15 June 2012

Print This

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has issued draft guidance which does not recommend ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in